Search

everythinglearnresearchcommunity

for

Search:↓

Chinese patients with systemic lupus erythematosus commonly experience oral ulcers, arthritis, alopecia, skin rash, and nephritis.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

More severe alopecia areata can lower quality of life.

Severe acne patients have higher inflammatory markers than healthy people.

The updated criteria improve the accuracy of diagnosing lupus.

The Pemphigus Disease Area Index and Autoimmune Bullous Skin Disorder Intensity Score are the best tools for assessing pemphigus severity.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

The InCISE score is a promising tool for assessing wound healing in head and neck surgery but needs more research for broader use.

An arthritis drug helped a person with severe hair loss regrow their hair.

Lipid Accumulation Product and Free Androgens Index are effective for assessing fatty liver disease risk in women with Polycystic Ovary Syndrome.

Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.

Azathioprine caused side effects in over half of the Korean pediatric inflammatory bowel disease patients, requiring close monitoring.

Alopecia affects patients' quality of life, with younger patients and longer-lasting hair loss experiencing greater impact.

Spironolactone helps reduce pain and lesions in hidradenitis suppurativa patients, and lower doses are also effective.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.